Home World News Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with... World News Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 636 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Zanubrutinib October 26, 2022 The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... March 13, 2020 Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 Load more HOT NEWS Rapid Genetic Test Could Help Guide Brain Cancer Surgery The Most Successful Female Singer Of The 1970s Disappeared. Now She’s... Facing Crisis After Crisis During Cancer: How to Cope Teacher Visits Student Battling Cancer At Home To Help With His...
